A Partially-blinded, Randomized, Placebo-controlled, Adaptive Single and Multiple Ascending Dose Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LHW090 in Healthy Volunteers and in Subjects With Renal Dysfunction

Trial Profile

A Partially-blinded, Randomized, Placebo-controlled, Adaptive Single and Multiple Ascending Dose Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LHW090 in Healthy Volunteers and in Subjects With Renal Dysfunction

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Mar 2017

At a glance

  • Drugs LHW 090 (Primary)
  • Indications Kidney disorders
  • Focus Adverse reactions
  • Sponsors Novartis Pharmaceuticals Corporation
  • Most Recent Events

    • 27 Aug 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Aug 2014 Planned End Date changed from 1 Jul 2014 to 1 Aug 2014 as reported by ClinicalTrials.gov.
    • 04 Aug 2014 Planned primary completion date changed from 1 Jul 2014 to 1 Aug 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top